Scarica l'app Stockscreener
0.959
2.14%
-0.021
Dopo l'orario di chiusura:
.95
-0.009
-0.94%
I Mab Adr Borsa (IMAB) Ultime notizie
I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies - MSN
I-Mab names Sean Fu as new CEO - Investing.com India
Invitation: Vallourec Q3 2024 Results ReleaseConference Call on Friday, November 15, 2024 - The Manila Times
I-Mab ADR (NASDAQ: IMAB) Stock: Investors Need To Know This - Stocks Register
Would I Buy Spectral AI Inc (NASDAQ: MDAI) Stock At Any Time In The Future? - Stocks Register
If You Don’t Buy Hub Cyber Security Ltd (NASDAQ: HUBC) Now, You’ll Kick Yourself Later - Stocks Register
Itau Unibanco Holding S.A. ADR (NYSE: ITUB) Still Pointing Upwards - Stocks Register
Is Veritone Inc’s (NASDAQ:VERI) Stock On The Decline? - Stocks Register
Cisco Systems, Inc. (NASDAQ: CSCO): What’s Next After The Stock Plunge? - Stocks Register
Should This Give Tandem Diabetes Care Inc (NASDAQ: TNDM) Investors Sleepless Nights? - Stocks Register
Kinross Gold Corp. (NYSE: KGC) Investors Should Be Worried About This. - Stocks Register
Where Do Analysts See Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Heading? - Stocks Register
Not A Good News For Keycorp (NYSE: KEY): The Stock Could Go Down -34.98 Percent More - Stocks Register
Analyst Forecast For Grab Holdings Limited (NASDAQ: GRAB) - Stocks Register
Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading - MSN
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
IMAB’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Company’s Banking Shares: Up -42.43% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
It makes sense and dollars to buy I-Mab ADR (IMAB) stock - SETE News
Ratio Revelations: I-Mab ADR (IMAB)’s Financial Metrics in the Spotlight - The Dwinnex
I-Mab ADR (IMAB) Stock: From Low to High in 52 Weeks - The InvestChronicle
IMAB’s price-to-sales ratio: A comparative analysis with its peers - US Post News
Piper Sandler maintains Overweight rating on I-Mab stock on drug data - Investing.com
I-Mab reveals Phase 1 data for lung cancer treatment - Investing.com
Federal Hill Taphouse & Kitchen abruptly closes - WPRI.com
I-Mab ADR (IMAB)’s stock price in review: A technical analysis - US Post News
There is no doubt that I-Mab ADR (IMAB) ticks all the boxes. - SETE News
Earnings call: I-MAB Biopharma discusses pipeline progress and financials - Investing.com India
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates - PR Newswire
Insight venture partners executives sell over $61 million in nCino shares By Investing.com - Investing.com India
I-Mab appoints new chairman and interim CEO - Investing.com
2024-07-15 | I-Mab Announces Leadership Transitions | NDAQ:IMAB | Press Release - Stockhouse Publishing
Financial Health Report: I-Mab ADR (IMAB)'s Ratios Tell a Tale – DWinneX - The Dwinnex
Teva Acquires Rights to Oncology Biosimilar Candidates - Yahoo News UK
It is Poised to be a Bull Market for I-Mab ADR (IMAB) – Sete News - SETE News
I-Mab names new Chief Medical Officer to enhance oncology pipeline - Investing.com India
I-Mab names new Chief Medical Officer to enhance oncology pipeline By Investing.com - Investing.com
I-Mab announces clinical trial collaboration with Bristol Myers - TipRanks
Analysts review I-Mab ADR's rating – Knox Daily - Knox Daily
I-Mab and Bristol Myers team up for cancer drug trial By Investing.com - Investing.com
Watch this stock's price performance: I-Mab ADR (NASDAQ:IMAB) – US Post News - US Post News
I-Mab ADR Inc. (IMAB) Price Performance: A Technical Analysis Perspective - The InvestChronicle
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier - Yahoo Lifestyle UK
Check out these key findings about I-Mab ADR (IMAB) – Sete News - SETE News
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 - GlobeNewswire Inc.
AbbVie Partners With Chinese Biotech for Cancer Candidate - Yahoo News NZ
Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks - Yahoo Lifestyle UK
Patent Law Changes Pose Threat to I-Mab Adr's Drug Candidate ProtectionTipRanks.com - TipRanks
I-Mab Announces CMO Transition, Interim Successor NamedTipRanks.com - TipRanks
I-Mab Finalizes Divestiture and Resolves ObligationsTipRanks.com - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature.com
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 - PR Newswire
Effects of a monoclonal antibody against (pro)renin receptor on gliomagenesis - Nature.com
Market Brief: Will the December CPI Report Help Further Tame Inflation Fears? - Morningstar
Morningstar’s Best- and Worst-Performing Stocks: 2022 - Morningstar
The Cheapest Stock in the World - Morningstar.ca
10 of the Cheapest Stocks of 2022 - Morningstar
Why Are Some China Healthcare Stocks Up 50%? - HK.Morningstar.com
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage - Nature.com
The Best- and Worst-Performing Stocks: Q3 2022 - Morningstar
I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal - Yahoo New Zealand News
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):